Abstract

The present application relates to novel pharmaceutical dosage forms comprising potent and selective inhibitors of TASK-1 and/or TASK-3 channels and use thereof for the treatment and/or prevention of respiratory disorders, including sleep-related respiratory disorders such as obstructive and central sleep apnoeas and snoring.